Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
Status:
Completed
Trial end date:
2021-05-03
Target enrollment:
Participant gender:
Summary
Nidufexor addresses fibrosis, oxidative stress, inflammation and cell death, and therefore
has the potential to improve the management of diabetic kidney disease when added to the
standard of care (angiotensin converting enzyme inhibitor or angiotensin receptor blocker).
This non-confirmatory Phase 2 study is designed to determine the safety, tolerability,
efficacy, pharmacokinetics and pharmacodynamics of nidufexor in combination with angiotensin
converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at a dose level that
is standard of care as judged by the study doctor in patients with type 2 diabetes and
nephropathy.